| Z05429 | |
|
|
|
| ¥123,118.00 | |
|
|
|
|
|
|
| Ask us a question | |
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity | > 95% as determined by BisTris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 34.7 kDa(IL-12B) & 25.5 kDa(IL-12A) | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 40-45 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
| Target Background | Interleukin 12 (IL-12) is a pleiotropic cytokine that plays an essential role in Th1-type immune response against cancer, a condition where cells in a particular part of the body grow and reproduce uncontrollably. |
| Synonyms | CLMF; CLMF2; IL-12A; IL-12B; IL12; IL12 p70; IMD28; IMD29; NFSK; NKSF1; NKSF2; P35; IL-12 subunit p35; IL12A; interleukin 12 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
